For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Colostrinin vs Semax

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

ColostrininSemax
CategoryNootropic & CognitiveNootropic & Cognitive
Also known asPRP (proline-rich polypeptide), ND, colostrum neuropeptide, CLN, ovine proline-rich polypeptideACTH(4-7)PGP, Met-Glu-His-Phe-Pro-Gly-Pro
EvidenceResearch-stageInvestigational (in trials)
Dosing range100mcg–400mcg mcg, sublingual, on a 3 days on / 3 days off cycle200mcg–900mcg mcg, Once or twice daily (intranasal most common)
AdministrationSublingual tablet/dropIntranasal (preferred — high CNS bioavailability), Subcutaneous injection
Key side effectsGenerally well-tolerated, Mild GI discomfort, Rare hypersensitivity (relevant for dairy protein sensitivity), Mild fatigue (initial days)Mild anxiety or restlessness at high doses, Nasal irritation (intranasal route), Increased energy / difficulty sleeping if dosed too late in the day, Mild appetite suppression
Cited sources2 references3 references

Key differences

  • Evidence level differs: Colostrinin is research-stage, while Semax is investigational (in trials).
  • Administration: Colostrinin — Sublingual tablet/drop; Semax — Intranasal (preferred — high CNS bioavailability), Subcutaneous injection.
  • Frequency: Colostrinin is typically sublingual, on a 3 days on / 3 days off cycle; Semax is Once or twice daily (intranasal most common).
  • Research depth: this profile cites 2 sources for Colostrinin vs 3 for Semax.

How each works

Colostrinin

Colostrinin modulates dendritic cell maturation and shifts cytokine balance toward anti-inflammatory patterns (reduced IL-6, TNF-α; increased IL-10). In neurological models, it reduces amyloid-β aggregation, decreases oxidative stress, and upregulates NGF while modulating the HPA axis stress response. A Polish double-blind trial showed statistically significant cognitive stabilization in mild-to-moderate AD patients over 15 weeks.

Semax

Semax increases BDNF expression in the hippocampus and frontal cortex by 1.3–1.6x at research doses in rodent models. It also upregulates NGF (nerve growth factor) and modulates serotonin, dopamine, and NMDA receptor systems. Russian clinical data (not yet replicated in Western trials) suggests efficacy in ischemic stroke recovery, ADHD, glaucoma, and cognitive decline. The Pro-Gly-Pro C-terminal extension dramatically improves resistance to enzymatic degradation compared to native ACTH(4-7).

Read the full Colostrinin profileRead the full Semax profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.